| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D Umbricht, D Javitt, G Novak, J Bates, S Pollack, J Lieberman, J Kan. Effects of clozapine on auditory event-related potentials in schizophrenia. Biological psychiatry. vol 44. issue 8. 1999-01-29. PMID:9798075. |
effects of clozapine on auditory event-related potentials in schizophrenia. |
1999-01-29 |
2023-08-12 |
Not clear |
| R Rosenheck, L Dunn, M Peszke, J Cramer, W Xu, J Thomas, D Charne. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The American journal of psychiatry. vol 156. issue 1. 1999-01-27. PMID:9892302. |
impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. |
1999-01-27 |
2023-08-12 |
Not clear |
| R Rosenheck, L Dunn, M Peszke, J Cramer, W Xu, J Thomas, D Charne. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The American journal of psychiatry. vol 156. issue 1. 1999-01-27. PMID:9892302. |
department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1999-01-27 |
2023-08-12 |
Not clear |
| R Rosenheck, L Dunn, M Peszke, J Cramer, W Xu, J Thomas, D Charne. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The American journal of psychiatry. vol 156. issue 1. 1999-01-27. PMID:9892302. |
this study compared the effect of clozapine and haloperidol on positive and negative symptoms of schizophrenia and in patients with high levels of negative symptoms or the deficit syndrome. |
1999-01-27 |
2023-08-12 |
Not clear |
| S G Potkin, Y Jin, B G Bunney, J Costa, B Gulasekara. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 1. 1999-01-27. PMID:9892314. |
effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. |
1999-01-27 |
2023-08-12 |
Not clear |
| S G Potkin, Y Jin, B G Bunney, J Costa, B Gulasekara. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 1. 1999-01-27. PMID:9892314. |
the focus of this study was the systematic evaluation of the clinical effects of glycine as an adjunct to the atypical antipsychotic clozapine in the treatment of schizophrenia. |
1999-01-27 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Grabowski, R Douyon, J Thomas, W Henderson, D Charne. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health services research. vol 33. issue 5 Pt 1. 1999-01-07. PMID:9865219. |
multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. |
1999-01-07 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Grabowski, R Douyon, J Thomas, W Henderson, D Charne. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health services research. vol 33. issue 5 Pt 1. 1999-01-07. PMID:9865219. |
department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1999-01-07 |
2023-08-12 |
Not clear |
| R Rosenheck, J Cramer, W Xu, J Grabowski, R Douyon, J Thomas, W Henderson, D Charne. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health services research. vol 33. issue 5 Pt 1. 1999-01-07. PMID:9865219. |
to develop new methods for combining results from multiple outcome domains and to demonstrate their application in a study of the cost-effectiveness of clozapine in treating hospitalized patients with refractory schizophrenia. |
1999-01-07 |
2023-08-12 |
Not clear |
| P Bret, C Jolivel, M C Bret, S Veylit, C Martin, P Garci. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809242. |
although the acquisition cost of clozapine is high, cost effectiveness estimates in patients with treatment resistant schizophrenia suggest that the clinical benefits (improved psychopathology, social functioning and quality of life) of this drug may confer medium to long term economic benefits, primarily by reducing the need for psychiatric hospital service. |
1999-01-05 |
2023-08-12 |
Not clear |
| W J Naja, J P Reneric, M P Bouvar. [Atypical neuroleptics in the child and adolescent]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809243. |
the fda approval for clozapine in 1990 under several hematologic surveillance conditions has reactualized the debate on the use of atypical neuroleptics for adults with schizophrenia. |
1999-01-05 |
2023-08-12 |
human |
| W J Naja, J P Reneric, M P Bouvar. [Atypical neuroleptics in the child and adolescent]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809243. |
since 1992 several studies concerning children and adolescents show the efficiency and the tolerance of the clozapine and risperidone in various disorders, especially in very early onset schizophrenia (veos). |
1999-01-05 |
2023-08-12 |
human |
| D C Henderson, R A Nasrallah, D C Gof. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. The Journal of clinical psychiatry. vol 59. issue 11. 1999-01-05. PMID:9862604. |
switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. |
1999-01-05 |
2023-08-12 |
Not clear |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious in reducing the psychotic symptomatology of schizophrenia as well as inducing less extrapyramidal side-effects. |
1998-12-30 |
2023-08-12 |
human |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious and safe in the treatment of schizophrenia. |
1998-12-30 |
2023-08-12 |
human |
| R Rosenheck, W Lawson, J Crayton, J Cramer, W Xu, J Thomas, M Stolar, D Charne. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biological psychiatry. vol 44. issue 6. 1998-12-28. PMID:9777179. |
veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1998-12-28 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
we tested the hypothesis that the most severe schizophrenia requiring treatment with clozapine would particularly show these effects. |
1998-11-06 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
by the end of 1994, seventeen (22%) of a total 76 dsm-iii-r schizophrenia patients, had received clozapine treatment. |
1998-11-06 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
there was no evidence that severe schizophrenia requiring treatment with clozapine was associated with impaired intrauterine or post-natal development. |
1998-11-06 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, G Facciolà, M Fabrazzo, P Monteleone, M Maj, E Perucca, A P Caput. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690983. |
effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |